NasdaqGS - Nasdaq Real Time Price USD

BeiGene, Ltd. (ONC)

Compare
176.71
-1.17
(-0.66%)
At close: January 10 at 4:00:00 PM EST
176.38
-0.33
(-0.19%)
After hours: January 10 at 7:56:19 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
3,316,826.00
2,458,779.00
1,415,921.00
1,176,283.00
308,874.00
Cost of Revenue
539,361.00
379,920.00
286,475.00
164,906.00
70,657.00
Gross Profit
2,777,465.00
2,078,859.00
1,129,446.00
1,011,377.00
238,217.00
Operating Expense
3,650,034.00
3,286,595.00
2,919,111.00
2,450,112.00
1,895,899.00
Operating Income
-872,569.00
-1,207,736.00
-1,789,665.00
-1,438,735.00
-1,657,682.00
Net Non Operating Interest Income Expense
56,302.00
74,009.00
52,480.00
-15,757.00
1,998.00
Other Income Expense
17,845.00
307,891.00
-223,852.00
15,904.00
37,490.00
Pretax Income
-798,422.00
-825,836.00
-1,961,037.00
-1,438,588.00
-1,618,194.00
Tax Provision
62,036.00
55,872.00
42,778.00
19,228.00
10,397.00
Net Income Common Stockholders
-860,458.00
-881,708.00
-2,003,815.00
-1,457,816.00
-1,624,974.00
Diluted NI Available to Com Stockholders
-860,458.00
-881,708.00
-2,003,815.00
-1,457,816.00
-1,624,974.00
Basic EPS
-8.19
-8.45
-19.37
-15.73
-19.50
Diluted EPS
-8.19
-8.45
-19.37
-15.73
-19.50
Basic Average Shares
104,550.21
104,387.27
103,133.04
92,785.39
83,471.68
Diluted Average Shares
104,550.21
104,387.27
103,133.04
92,785.39
83,471.68
Total Operating Income as Reported
-872,569.00
-1,207,736.00
-1,789,665.00
-1,438,735.00
-1,657,682.00
Total Expenses
4,189,395.00
3,666,515.00
3,205,586.00
2,615,018.00
1,966,556.00
Net Income from Continuing & Discontinued Operation
-860,458.00
-881,708.00
-2,003,815.00
-1,457,816.00
-1,624,974.00
Normalized Income
-860,458.00
-881,708.00
-2,003,815.00
-1,457,816.00
-1,624,974.00
Interest Income
--
--
--
--
1,998.00
Net Interest Income
56,302.00
74,009.00
52,480.00
-15,757.00
1,998.00
EBIT
-872,569.00
-1,207,736.00
-1,789,665.00
-1,438,735.00
-1,657,682.00
EBITDA
-727,234.00
-1,120,061.00
-1,723,387.00
-1,392,278.00
-1,625,893.00
Reconciled Cost of Revenue
539,361.00
295,745.00
220,948.00
119,199.00
39,714.00
Reconciled Depreciation
145,335.00
87,675.00
66,278.00
46,457.00
31,789.00
Net Income from Continuing Operation Net Minority Interest
-860,458.00
-881,708.00
-2,003,815.00
-1,457,816.00
-1,624,974.00
Normalized EBITDA
-727,234.00
-1,120,061.00
-1,723,387.00
-1,392,278.00
-1,625,893.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 2/3/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RVMD Revolution Medicines, Inc.
41.78
-5.94%
 
ZBIO Zenas BioPharma, Inc.
8.12
-12.50%
 
CRNX Crinetics Pharmaceuticals, Inc.
40.59
-16.31%
 
LEGN Legend Biotech Corporation
33.62
+2.59%
 
BPMC Blueprint Medicines Corporation
87.43
-3.53%
 
KYMR Kymera Therapeutics, Inc.
38.17
-5.80%
 
ARGX argenx SE
656.26
+1.08%
 
ZLAB Zai Lab Limited
25.30
+4.12%
 
MOLN Molecular Partners AG
4.9837
-5.97%
 
ASND Ascendis Pharma A/S
129.19
-3.90%